These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10991865)

  • 1. Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males.
    Smith PF; Forrest A; Ballow CH; Martin DE; Proulx L
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2816-23. PubMed ID: 10991865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans.
    Smith PF; Forrest A; Ballow CH; Martin DE; Proulx L
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1609-15. PubMed ID: 10817717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate.
    Smith PF; Forrest A; Adams JM; Ballow CH
    J Clin Pharmacol; 2002 Jun; 42(6):658-61. PubMed ID: 12043954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
    de Muys JM; Gourdeau H; Nguyen-Ba N; Taylor DL; Ahmed PS; Mansour T; Locas C; Richard N; Wainberg MA; Rando RF
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1835-44. PubMed ID: 10428900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC).
    Richar N; Quan Y; Salomon H; Hsu M; Bedard J; Harrigan PR; Rando R; Mansour T; Bowlin TL; Wainberg MA
    Antivir Ther; 1999; 4(3):171-7. PubMed ID: 12731757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers.
    Holdich T; Shiveley L; Sawyer J
    Clin Drug Investig; 2006; 26(5):279-86. PubMed ID: 17163261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
    Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
    Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
    Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.
    Wang LH; Wiznia AA; Rathore MH; Chittick GE; Bakshi SS; Emmanuel PJ; Flynn PM
    Antimicrob Agents Chemother; 2004 Jan; 48(1):183-91. PubMed ID: 14693538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
    Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.
    Richard N; Salomon H; Oliveira M; Rando R; Mansour T; Gu Z; Wainberg MA
    Antivir Chem Chemother; 2000 Nov; 11(6):359-65. PubMed ID: 11227993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection.
    Cahn P; Rolon M; Cassetti I; Shiveley L; Holdich T; Sawyer J
    Clin Drug Investig; 2008; 28(2):129-38. PubMed ID: 18211121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
    Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
    Urata Y; Paintsil E; Cheng YC; Matsuda T; Sevinsky H; Hawthorne D; Bertz R; Hanna GJ; Grasela D; Hwang C
    J Clin Pharmacol; 2014 Jun; 54(6):657-64. PubMed ID: 24374821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.